First-line Treatment Study of Osimertinib With or Without Datopotamab Deruxtecan for EGFR Mutation-positive Advanced Non-small Cell Lung Cancer
Led by AstraZeneca · Updated on 2026-08-26
582
Participants Needed
167
Research Sites
179 weeks
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating the safety and effectiveness of osimertinib tablets combined with Datopotamab Deruxtecan intravenous infusion compared to osimertinib alone as a first treatment for participants with locally advanced or metastatic non-small cell lung cancer NSCLC that has specific EGFR mutations Ex19del andor L858R. This global Phase III, open-label, randomized study includes participants who have not received prior therapy for advanced disease, aiming to assess treatment benefits over approximately 8 years.
Participants are randomly assigned to one of two groups one group receives osimertinib 80 mg orally once daily plus Datopotamab Deruxtecan 6 mgkg by intravenous infusion every 3 weeks, while the other group receives osimertinib 80 mg orally once daily alone. Treatment continues until disease progression, unacceptable side effects, or other discontinuation reasons. Visits occur every 3 weeks during treatment, with additional assessments every 6 weeks from cycle 7 to cycle 17, then every 12 weeks for those on osimertinib alone or after discontinuing Datopotamab Deruxtecan.
Participants will attend regular visits for treatment administration and assessments, including scans and laboratory tests to monitor disease status and safety. Researchers will measure progression-free survival, overall survival, response rates, and the impact on brain metastases over the study period. Pharmacokinetics and immunogenicity of the drugs will also be evaluated. The study includes continuous safety monitoring and may last up to 8 years, with visits and evaluations scheduled throughout treatment and follow-up.
CONDITIONS
Brief Title
Phase III, Open-label Study of First-line Osimertinib With or Without Datopotamab Deruxtecan for EGFRm Locally Advanced or Metastatic Non-small Cell Lung Cancer
Research Team
A
AstraZeneca Clinical Study Information Center
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match. Sign up to get personalized trial recommendations delivered to your inbox.
This table compares participation in this trial with other options available for this condition. The information is drawn from published research and the trial’s study details and is provided for educational purposes only.
Factors
Osimertinib + Datopotamab Deruxtecan
Osimertinib alone
Osimertinib + chemotherapy
What this option is
Combination of osimertinib (EGFR‑targeted oral therapy) with datopotamab deruxtecan (TROP2‑targeted antibody‑drug conjugate) as first‑line treatment
Osimertinib monotherapy as first‑line EGFR‑targeted treatment
Osimertinib combined with platinum‑based chemotherapy is a current first‑line standard regimen for EGFR‑mutated advanced NSCLC
Role in trial
Investigational arm studied in this randomized trial
Active comparator arm in the trial
Not evaluated in this trial; added here for real‑world clinical context
Primary use or purpose
Evaluated as first‑line treatment to improve progression‑free survival compared to osimertinib alone
Standard first‑line EGFR‑targeted therapy by itself
Established first‑line intensification strategy to delay resistance and improve survival
How it is given or performed
Oral osimertinib daily plus intravenous infusion of datopotamab deruxtecan every 3 weeks
Osimertinib given orally once daily
Osimertinib oral daily plus platinum‑based chemotherapy on standard schedule (per guideline use)
Evidence status
Efficacy is investigational; trial ongoing, outcomes pending
Osimertinib monotherapy has proven effectiveness as first‑line EGFR‑targeted therapy
Combination with chemotherapy has shown improved progression‑free and overall survival compared to osimertinib alone in recent randomized trials
Important risks
Risks include potential toxicity of ADC plus EGFR‑TKI, but safety profile remains under evaluation
Known risks of osimertinib include typical EGFR‑TKI adverse effects
Adding chemotherapy increases toxicity compared to osimertinib alone
Important limitations
Efficacy and safety unknown as trial is ongoing; not yet practice‑established
Single‑agent approach may allow earlier development of resistance compared to intensified regimens
Requires chemotherapy where toxicity and patient suitability may limit use
Disclaimer: This comparison is created with the help of artificial intelligence(AI) and may contain errors or missing information. It is not medical advice and does not mean one option is better or safer than another. Clinical trials are still being studied, and joining a trial is your choice. Please consult your healthcare professional before making any decisions.
Who Can Participate
Age: 18Years +
All Genders
Eligibility Criteria
You may qualify if you...
Participant must be 18 years or older.
Diagnosed with nonsquamous non-small cell lung cancer, with adenocarcinoma as predominant histology.
Have stage IIIB, IIIC, IV metastatic or recurrent NSCLC not suitable for curative surgery or chemoradiation.
No prior EGFR TKI or systemic therapy for advanced NSCLC.
Tumor confirmed to have EGFR mutations Ex19del or L858R.
Provide tumor tissue sample for central EGFR mutation confirmation.
WHO performance status of 0 or 1.
At least one measurable lesion not previously irradiated.
Adequate bone marrow and organ function before starting treatment.
You will not qualify if you...
Any severe or uncontrolled systemic diseases that may affect participation.
Refractory nausea, vomiting, or gastrointestinal conditions preventing drug absorption.
History of another primary cancer.
Spinal cord compression or unstable brain metastases.
Significant corneal disease.
Active or uncontrolled hepatitis B or C infection.
History or suspected interstitial lung disease or pneumonitis.
Severe lung function problems from other pulmonary illnesses.
Your Study Journey
Screening
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Treatment
Duration - Approximately 8 years, event-driven
Participants receive either osimertinib alone daily or osimertinib combined with Datopotamab Deruxtecan infusion every 3 weeks until disease progression or unacceptable side effects.
Visits every 3 weeks; some participants have additional assessments every 6 or 12 weeks as specified
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Similar Trials
Using 3-D Virtual Lung Resection to Predict Lung Function After VATS Surgery for Non-Small Cell Lung Cancer
Early Evaluation of Neoadjuvant Immunotherapy Response
Using 68Ga-grazytracer PETCT in Resectable Non-Small Cell Lung Cancer
Patients Aged 18 to 75 Years
Evaluating Calderasib with Subcutaneous Pembrolizumab Versus Pembrolizumab Plus Chemotherapy
for KRAS G12C-Mutant Advanced Non-Small Cell Lung Cancer
Randomized Study of Adjuvant Cemiplimab Versus Observation in Patients With Surgically Removed Stage II-IIIA Non-Small Cell Lung Cancer Without Prior Chemotherapy
Evaluating Adjuvant Intismeran With or Without Pembrolizumab Coformulated With Berahyaluronidase Alfa Compared to Placebo in High-Risk Stage I Non-Small Cell Lung Cancer
Study of MK-1084 Plus Durvalumab Versus Placebo Plus Durvalumab in People With Locally Advanced KRAS G12C-Mutant Non-Small Cell Lung Cancer After Chemoradiotherapy
Phase 2 Study of TQB2102 Injection for Treating Locally Advanced or Metastatic Non-Small Cell Lung Cancer with HER2 Gene Abnormality
Phase I Study of Intravenous CEA-Targeted CAR-T Therapy for Advanced CEA Positive Solid Tumors
Testing Safety and Effectiveness of BNT326 and Pumitamig Combination Therapy in Advanced Non-small Cell Lung Cancer
Phase IIIb Study to Evaluate the Safety and Effectiveness of Vebreltinib PLB1001 in Adults With Advanced or Metastatic Non-Small Cell Lung Cancer Having MET Exon 14 Mutation
Have more questions? Get in touch with our team for quick support
Published Research Related To This Trial
TROPION-Lung14 study protocol: a phase III study of osimertinib in combination with datopotamab deruxtecan versus osimertinib alone as first-line treatment for patients with EGFR-mutated locally advanced or metastatic non-small cell lung cancer.